Untapped NME Opportunity AyuVis focuses on novel molecular entities that modulate innate immunity, presenting potential collaboration avenues with pharma firms seeking first-in-class anti-inflammatory, antimicrobial, and immune-modulating therapies.

orphan Designation Lead candidate has FDA orphan drug and rare pediatric disease designations for preventing bronchopulmonary dysplasia, suggesting partners may pursue accelerated development paths and favorable regulatory support for pediatric inflammatory lung conditions.

Small Team, Big Impact With a compact team and ongoing external funding, AyuVis offers a lean collaboration profile, enabling agile partnerships, fast decision cycles, and cost-effective co-development opportunities for early-stage programs.

Recent Funding Momentum Grants and NIH support totaling several million dollars underscore validation of the platform and readiness for first-in-human trials, signaling attractive risk-reduction angles for potential co-investors and collaborators.

Strategic Partnerships Past and current partnerships with academic centers and incubators bolster credibility and access to translational resources, presenting conversation starters for licensing, research collaborations, or sponsored programs with larger biopharma.